[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer-s-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer-s-disease":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,48,61,89,117,141,164,190,217,240,259,288,316,339,365,388,410,436,466,506,530,554,581,608,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054007","phase-1-pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-disease-ad-or-mild-cognitive-impairment-mci-100054007",false,"NCT07169630","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)","* INCLUSION CRITERIA:\n\nParticipants will be referred by a physician with the suspected diagnosis of AD or MCI. However, the PI of this protocol will provide the final diagnosis. For this reason, this protocol will have just one consent form for participants suspected of having either AD or MCI.\n\nAD and MCI Study Groups:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n* Have been diagnosed by a neurologist or psychiatrist with MCI or AD.\n* Be in good general health as evidenced by medical history and physical examination.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nHealthy Volunteers:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Able to provide informed consent.\n* Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth the study groups will be excluded if they meet any of the following criteria:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Participants should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n* Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the volunteer and\u002For caregiver during the screening visit.\n* Participants must not have substance use disorder or alcohol use disorder.\n* Participants should not be under treatment or previously treated with an amyloid antibody such as lecanemab.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n* Pregnancy or breast feeding.\n* HIV infection.\n* Non-English speaking participants.\n\nExclusion of Children:\n\nInclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.\n\nExclusion of Pregnant or Breastfeeding Women:\n\nPregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will not require contraception for this protocol to allow participants autonomy in medical decision-making. However, while we will not require contraception for woman of childbearing potential, we will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant\n\nExclusion of Participants who are HIV Positive:\n\nPersons with HIV infection are excluded because HIV infection itself may change cAMP signaling.\n\nExclusion of Non-English-Speaking Participants:\n\nNon-English-speaking participants will be excluded from participation in this study because neuropsychological testing is required by this protocol. This testing, which is critical for interpreting study results, has not been validated in other languages or when using a translator.",true,"ALL","50 Years","100 Years",{"count":22,"type":23},90,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","Background:\n\nAbout 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.\n\nObjective:\n\nTo test whether medical imaging using a new radiotracer (\\[18F\\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.\n\nEligibility:\n\nPeople aged 50 years and older with AD or MCI. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have up to 5 clinic visits with 3 imaging scans of the brain.\n\nThey will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.\n\nParticipants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.\n\nParticipants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....",[29,30,31],"Alzheimer s Disease","Mild Cognitive Impairment","Healthy",[33,34],"18F-PF-06445974","PET Imaging","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":23},"2026-07-16",{"date":43,"type":23},"2030-04-11",{"name":45,"class":46},"National Institute of Mental Health (NIMH)","NIH",1,{"id":49,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":50,"targetDuration":4,"studyType":24,"phases":51,"briefSummary":27,"conditions":52,"keywords":53,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":60,"locationsCount":47},"100605983",{"count":22,"type":23},[26],[29,30,31],[33,34],"2026-07-01",{"date":56,"type":39},"2026-07-02",{"date":58,"type":23},"2026-07-07",{"date":43,"type":23},{"name":45,"class":46},{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":24,"phases":71,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":47},"100645330","efficacy-of-lymphatic-venous-anastomosis-plus-donepezil-versus-donepezil-alone-for-alzheimers-disease-100645330","NCT07680660","Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's Disease","A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Cervical Lymph Vessel\u002FNode-venous Anastomosis Combined With Donepezil Versus Donepezil Alone in the Treatment of Alzheimer's Disease","Inclusion Criteria\n\n1. The patient or guardian signs the informed consent form;\n2. Age 50-80 years (≥50 years, ≤80 years), male or female;\n3. The first diagnosis is Alzheimer's disease with dementia;\n4. MMSE score ≤24;\n5. Positive β-amyloid protein PET imaging findings;\n6. HAMD score ≤17;\n7. Hachinski score ≤7;\n8. No AD-related drug treatment has been received within the past 1 month;\n9. ASA grade 1-3 (≥ grade 1, ≤ grade 3).\n10. CDR-SB score of 9.5-15.5\n\nExclusion Criteria\n\n1. Presence of contraindications to MRI, ICG angiography, or PET scan;\n2. Presence of contraindications to lumbar puncture;\n3. Severe heart disease or unstable hemodynamic status;\n4. Severe lung disease, including severe obstructive, restrictive, or mixed ventilatory dysfunction, or acute inflammation within 3 months;\n5. Hepatic insufficiency, AST or ALT \\>3 times the upper limit of normal;\n6. Renal insufficiency, GFR \\\u003C60 mL\u002Fmin or need for blood purification treatment;\n7. MRI indicates active or acute intracranial lesions, including intracranial infection, space-occupying lesions, major hemorrhage, and ≥4 lobar microbleeds, etc.;\n8. History of cerebral hemorrhage or cerebral infarction with severe residual neurological dysfunction;\n9. Blood diseases, bleeding\u002Fcoagulation disorders, coagulation dysfunction;\n10. Abnormal thyroid function;\n11. Moderate or severe stenosis of intracranial or cervical vessels with severe residual neurological dysfunction;\n12. Severe hypertension not effectively controlled, systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;\n13. The disease requires systemic use of steroids;\n14. Drug addiction (including alcohol, narcotics, and alcohol dependence);\n15. Severe infectious diseases, including HIV positivity, severe infection, etc.;\n16. Severe psychiatric disease or potential suicide risk;\n17. Within 3 years after radical surgery for malignant tumor;\n18. Participation in other interventional clinical trials within the past three months;\n19. In the physician's judgment, poor compliance, inability to complete, or unwillingness to cooperate with regular postoperative follow-up;\n20. Other circumstances that the physician considers unsuitable for this clinical trial.\n21. Anti-Aβ monoclonal antibody treatment has been received within half a year","80 Years",{"count":70,"type":23},216,[72],"NA","This study employed a multicenter, randomized controlled trial (RCT) design to evaluate the efficacy and safety of deep cervical lymphatic\u002Flymph node-venous anastomosis combined with oral donepezil compared to donepezil monotherapy in patients with Alzheimer's disease and moderate dementia. Participants were randomized using a central randomization system with stratified block design, with the study center and age group (50-64 years, 65-80 years) as stratification factors. While study participants and surgical investigators could not be blinded due to the nature of the intervention, efficacy assessors and imaging specialists remained blinded to ensure the objectivity and reliability of the findings. The intervention group received deep cervical lymphatic\u002Flymph node-venous anastomosis (detailed surgical procedure is specified in the protocol) in combination with oral donepezil (5-10 mg\u002Fday), while the control group received oral donepezil alone. The total treatment and follow-up period was 18 months, with assessments conducted at baseline, 1 week, 1, 3, 6, 12, and 18 months post-operation. These included neuropsychological evaluations (MMSE, MoCA, CDR, BADL, IADL, NPI, AES), neuroimaging (MRI, PET, ultrasound), fluid biomarker analyses (CSF and blood levels of Aβ, Tau, neuroinflammatory factors, etc.), and safety monitoring. The primary efficacy endpoint was the change in CDR-SB score at 12 months post-treatment. Secondary endpoints included changes in multiple cognitive scales, neuroimaging metrics, and biomarkers at 18 months. Safety indicators encompassed adverse event recording, vital signs, and laboratory tests.",[29],[76,77,78],"cervical lymph vessel\u002Fnode-venous anastomosis","LVA","Alzheimer","NOT_YET_RECRUITING","2026-06-25",{"date":56,"type":39},{"date":83,"type":23},"2026-07-15",{"date":85,"type":23},"2029-03-31",{"name":87,"class":88},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","OTHER",{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":24,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":47},"100644705","brain-wave-informed-non-invasive-brain-stimulation-improving-neural-networks-of-working-memory-in-dementia-a-proof-of-concept-study-100644705","NCT07673770","Brain Wave Informed Non-invasive Brain Stimulation: Improving Neural Networks of Working Memory in Dementia: a Proof-of-concept Study","BWIBS-WM","Inclusion Criteria:\n\n* Individuals must be diagnosed with Alzheimer's Disease or related dementias by a clinician.\n* Individuals must exhibit adequate oral communication skills and cognitive function sufficient to obtain a score above 10 on the MMSE\n* Instructions will be delivered in English; therefore participants must demonstrate an understanding of instruction provided in English.\n* Individuals must be at least 55 years or older\n\nExclusion Criteria:\n\n* Contraindications to TMS; presence of a pacemaker, metal\u002Felectrical\u002Fmagnetic implants not including titanium, known history of untreated or uncontrolled psychological disorders, pregnancy, history of seizure or diagnoses of epilepsy, are taking any prescription medications that increase the risk of seizure.\n* Allergy to rubbing alcohol, which is needed to prepare electromyography for TMS","55 Years",{"count":98,"type":23},30,[72],"Working memory helps us hold information for a short time so one can think and make decisions. It keeps thoughts on track. As one gets older, working memory gets weaker. In people with dementia, it gets much worse, making it harder to talk with others, follow directions, or remember things like shopping lists.\n\nThis may happen because brain waves that support working memory fall out of sync. Researchers can see these brain waves using a test called EEG. In this study, the investigators will try to get these brain waves back in sync using a safe, non-invasive form of brain stimulation called transcranial magnetic stimulation (TMS), and will time it to each person's brain waves to make it more effective. The goal is to improve working memory in people with dementia. If successful, dementia patients may be able to be more independent taking pressure off their families.",[102,29],"Dementia",[102,104,105,106,107],"Alzheimer's Disease","transcranial magnetic stimulation","eeg","electroencephalography","2026-06-24",{"date":110,"type":39},"2026-06-29",{"date":112,"type":23},"2026-06-01",{"date":114,"type":23},"2028-08-01",{"name":116,"class":88},"McMaster University",{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":18,"minAge":96,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":47},"100643954","non-invasive-brain-stimulation-for-memory-loss-in-early-alzheimers-disease-100643954","NCT07667478","NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for enrollment:\n\n* A clinical diagnosis of early AD, defined as either mild cognitive impairment (MCI) due to AD or mild dementia due to AD;\n* Evidence of cognitive impairment, characterized by a MMSE score between 20 and 28 and\u002For a CDR-Sum of Boxes score between 0.5 and 8, consistent with the contemporary definitions used in early AD in clinical trials; and\n* Biomarker confirmation of AD pathology, demonstrated by a positive plasma phosphorylated tau-217 (p-tau217) result according to the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic guidelines.\n\nExclusion Criteria:\n\n* Exclusion criteria include evidence of other neurological, psychiatric, or systemic conditions that could cause cognitive and functional impairments (e.g., substantial concomitant cerebrovascular disease, alcoholism, certain medications that could have a substantial effect on cognition, untreated major depressive disorder, and heart, renal or hepatic failure).\n* Individuals who have contraindications to receiving rTMS, including a history of seizures or any non-removable metal in their heads or within 12 inches of the TMS coil will be excluded.","90 Years",{"count":125,"type":23},40,[72],"The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD). The study will also evaluate the safety of this approach.\n\nThe main questions it aims to answer are:\n\n* Does rTMS applied to the cerebellum improve short-term memory in people with early AD?\n* How does this stimulation affect brain activity and connectivity measured by MRI?\n\nResearchers will compare active rTMS to sham rTMS (a look-alike procedure that does not deliver brain stimulation) to see if rTMS works to improve memory.\n\nParticipants will:\n\n* Complete a screening visit with medical and memory assessments\n* Be randomly assigned to receive either active rTMS or sham rTMS (neither participants nor researchers will know the assignment during treatment)\n* Receive 20 rTMS sessions over 4 weeks (about 20 to 30 minutes per session)\n* Undergo two MRI scans, one before and one after treatment\n* Complete memory and thinking tests and questionnaires at baseline, immediately after treatment, and at 3- and 6-month follow-up visits\n\nParticipation in the study will last about 6 months.\n\nThe rTMS is generally well tolerated. The most common side effects include mild headache and scalp discomfort during treatment, which are usually short-lasting. MRI is non-invasive and safe for most people. Study procedures will be reviewed to ensure participant safety.\n\nParticipants may or may not benefit directly from this study. People who receive active rTMS may experience improvement in memory. This research may help improve understanding of memory function in AD and support development of new treatments.",[29,129,130],"Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease","Mild Dementia",[132,30,133],"Alzheimer's disease","Mild dementia",{"date":80,"type":39},{"date":136,"type":39},"2026-04-15",{"date":138,"type":23},"2031-04-14",{"name":140,"class":88},"Chi-Ying (Roy) Lin",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":24,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":47},"100644727","effects-of-x-box-kinect-360-in-alzheimers-disease-100644727","NCT07673263","Effects of X Box Kinect 360 in Alzheimer's Disease","Effect of 3D Kinect Games With Google Cardboard on Motor Control, Cognition, and Quality of Life in Mild to Moderate Alzheimer's Patient","AD Alzheimer'","Inclusion Criteria\n\n* Alzheimer's disease of age between 50-85 years.\n* Diagnosed AD stage Mild to Moderate.\n\nExclusion Criteria:\n\n* Undiagnosed AD patients.\n* Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.","85 Years",{"count":151,"type":23},38,[72],"Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).",[29],[156],"Alzheimer Disease, Virtual Reality, Kinect xbox 360","2026-06-23",{"date":110,"type":39},{"date":108,"type":23},{"date":161,"type":23},"2026-08-15",{"name":163,"class":88},"Ziauddin University",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":68,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100643862","deep-cervical-lymphovenous-anastomosis-for-severe-alzheimers-disease-100643862","NCT07669272","Deep Cervical Lymphovenous Anastomosis for Severe Alzheimer's Disease","A Single-arm, Prospective, Self-controlled Study on Efficacy and Safety of Deep Cervical Lymphovenous Anastomosis for Neurological Function in Patients With Severe Alzheimer's Disease","DCLVA-AD","Inclusion Criteria:\n\n* Meet the 2011 NIA-AA clinical diagnostic criteria for probable Alzheimer's disease dementia and the 2018 NIA-AA research framework biomarker criteria for AD.\n* Aged 50 to 80 years (inclusive) at the time of signing informed consent.\n* Severe cognitive dysfunction: Mini-Mental State Examination (MMSE) score \\\u003C 10 points.\n* Progressive cognitive deterioration for more than 6 months reported by patient or caregiver.\n* No clinical improvement after more than 6 months of standardized drug treatment.\n* Have a designated study companion who signs informed consent, contacts the patient at least 10 hours per week and accompanies study visits.\n* Able to complete scale assessments and examinations independently or with companion assistance.\n* Voluntarily comply with study procedures, examinations and surgical treatment.\n* Patient or legal representative can sign written informed consent and abide by trial requirements.\n* Patients and families are informed of study purpose, expected efficacy and potential risks, and voluntarily provide biological samples and participate in the study.\n\nExclusion Criteria:\n\n* Severe central nervous system diseases (other than AD) that affect cognitive function or study compliance.\n* Severe\u002Funstable systemic diseases (cardiovascular, hepatic, renal, respiratory, endocrine, hematological, psychiatric diseases); life expectancy less than 24 months.\n* Surgical contraindications: severe coagulation disorders, severe -cardiopulmonary diseases (myocardial infarction\u002Frespiratory failure within recent 30 days); severe liver damage (ALT\u002FAST \\> 3 times upper limit of normal); severe renal insufficiency (eGFR \\\u003C 30ml\u002Fmin).\n* Severe primary mental disorders (other than AD) that interfere with efficacy evaluation and cognitive assessment.\n* History of intracranial hemorrhage or craniocerebral trauma within recent 1 year.\n* Alcohol or drug abuse\u002Fdependence within recent 1 year.\n* Allergy to indocyanine green, gadolinium contrast agent, 18F-florbetapir or 18F-flortaucipir.\n* Contraindications for PET examination.\n* Other conditions judged by investigators unsuitable for enrollment.",{"count":173,"type":23},59,[72],"Alzheimer's disease (AD) is a severe neurodegenerative disease with heavy social burden. Current drugs cannot reverse disease progression. Brain glymphatic system and meningeal lymphatic dysfunction lead to impaired clearance of Aβ and Tau protein, which is an important pathogenesis of AD. Deep cervical lymphovenous anastomosis (DCLVA) can improve intracranial lymphatic drainage, promote the clearance of toxic proteins, and improve neurological function. This is a single-arm, prospective, self-controlled study to enroll 59 patients with severe AD (MMSE \\\u003C 10). All patients receive bilateral DCLVA plus routine medication. The primary endpoint is change of CDR-SB score at 12 months post-operation. Secondary endpoints include MMSE, ZBI scores and Aβ PET-CT Centiloid value. This study aims to verify the efficacy and safety of DCLVA for severe AD.",[29],[178,179,180,181],"Alzheimer Disease","Severe Dementia","Cognitive Impairment","Neurodegenerative Disease","2026-06-21",{"date":80,"type":39},{"date":185,"type":23},"2026-10-01",{"date":187,"type":23},"2029-09-30",{"name":189,"class":88},"Southwest Hospital, China",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":17,"sex":18,"minAge":197,"maxAge":96,"enrollmentInfo":198,"targetDuration":4,"studyType":24,"phases":200,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":47},"100641667","phase-1-sad-study-of-cgb3002-in-healthy-participants-100641667","NCT07660341","SAD Study of CGB3002 in Healthy Participants","A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single Ascending Doses of CGB3002 in Healthy Participants","Inclusion Criteria:\n\n* Must have signed written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.\n* Age≥18 years and\\\u003C55 years at the time of consent, healthy participants, male or female.\n* A body mass index (BMI) of 18 to 32 kg\u002Fm2 (cutoff inclusive), with male participants weighing no less than 50 kg, female participants weighing no less than 40 kg.\n* Males and females of childbearing potential agree to have no plans for childbearing, use reliable contraceptive measures and not to donate sperm or ova from 30 days prior to dosing until 120 days after dosing. For females of childbearing potential, hormonal contraceptives should begin at least 1 month prior to screening to ensure contraceptive is in full effect.\n\nExclusion Criteria:\n\n* A known history of clinically significant drug allergy or atopic allergic disease (asthma, urticaria, eczematous dermatitis) or a known history of allergy to biologics or any excipients in biologics, fully resolved childhood asthma can be enrolled.\n* Any disease that may affect the safety evaluation of the participants or the in vivo process of the investigational product, including the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematopoietic system, metabolic endocrine system, etc.\n* Use of prescription drugs within 14 days or five half-lives (whichever is longer) prior study drug administration, unless determined by the Investigator and Sponsor to be non-interfering (e.g., hormonal contraceptives).\n* Use of over-the-counter (OTC) or Chinese herbal medicine within 7 days or 5 half-lives (whichever is longer) prior to study drug administration, unless determined by the Investigator and Sponsor to be non-interfering.\n* With a history of drug abuse within 12 months prior to dosing.\n* Cannot tolerate punction, have a history of needle fainting or blood fainting.\n* Have participated in clinical trials, whether for drugs or medical devices, within 30 days prior to administration or within 7 times the known elimination half-life, whichever is longer.\n* Blood donation or significant blood loss (\\> 300 mL) within 30 days prior to dosing, and planning to blood donate during the study.\n* Any vaccinations with a live vaccine (excluding influenza vaccine) within 60 days prior to dosing.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥1.5×ULN at screening or Day -2. Total bilirubin (TBIL) \\> ULN at screening or Day -2(except in those due to findings consistent with Gilbert's disease).\n* Estimated creatinine clearance \\\u003C 80 mL\u002F min (Cockroft-Gault equation) at screening or Day-2.\n* Test positive for syphilis, hepatitis B virus surface antigen (HbsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCV-Ab) or HIV antibody at screening.\n* Urine drug screening positive at screening or Day-2.\n* Have a head MRI demonstrating either cerebral microhemorrhages, or superficial siderosis, or prior evidence of microhemorrhage, or any other major intracranial pathology.\n* Still needed or planned to engage in vigorous physical activity or exercise during study participation.\n* Other conditions deemed inappropriate by the investigator to participate in the clinical trial.","18 Years",{"count":199,"type":23},46,[26],"This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single ascending IV doses of CGB3002 in healthy participants. CGB3002 is being developed to treat Alzheimer's Disease.",[29],[204,205,206],"CGB3002","Healthy participants","Australia","2026-06-16",{"date":209,"type":39},"2026-06-22",{"date":211,"type":23},"2026-06-30",{"date":213,"type":23},"2027-04-30",{"name":215,"class":216},"ChainGen Biopharma Ltd","INDUSTRY",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":149,"enrollmentInfo":225,"targetDuration":4,"studyType":24,"phases":227,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":4},"100642975","phase-1-a-study-of-the-metabolic-reconstruction-oral-biologics-gut-x-001-medication-in-people-with-alzheimers-disease-escape-ad-100642975","NCT07591727","A Study of the Metabolic Reconstruction Oral Biologics (Gut-X-001) Medication in People With Alzheimer's Disease (ESCAPE-AD)","Efficacy, Safety, and Feasibility of Metabolic ReConstruction Oral Biologics (Gut-X-001) in Patients With Alzheimer's Disease: An Exploratory Clinical Trial （ESCAPE-AD）","ESCAPE-AD","Inclusion Criteria\n\n1. Age ≥50 and ≤85 years.\n2. Diagnosis of Alzheimer's disease confirmed by a qualified neurologist based on the 2024 National Institute on Aging - Alzheimer's Association (NIA-AA) diagnostic criteria, with at least one abnormal core biomarker, including amyloid PET, CSF Aβ42\u002F40, phosphorylated tau181 (p-tau181)\u002FAβ42, total tau (t-tau)\u002FAβ42, or plasma p-tau217.\n3. MMSE score meeting the following criteria:\n\n   If years of education ≤6: MMSE score between 16 and 24 (inclusive); If years of education \\>6: MMSE score between 18 and 27 (inclusive).\n4. Clinical Dementia Rating (CDR) global score of 0.5 (for MCI due to AD) or 1.0 (for mild AD dementia).\n5. If receiving acetylcholinesterase inhibitor (AChEI) and\u002For memantine therapy, the dose must have been stable for at least 3 months prior to screening.\n6. Participants must have a reliable caregiver who has frequent contact with the participant (at least 4 days per week and at least 2 hours per day). The caregiver must accompany the participant to all study visits, provide meaningful input for scale assessments through sufficient interaction with the participant, and remain consistent throughout the study period wherever possible.\n7. The participant or their legally authorized representative is able and willing to provide written informed consent.\n\nExclusion Criteria\n\n1. Presence of other conditions that may contribute to cognitive impairment, including neurological disorders (e.g., vascular cognitive impairment, Parkinson's disease, frontotemporal dementia, Lewy body dementia) or psychiatric and affective disorders (e.g., severe anxiety\u002Fdepression, schizophrenia).\n2. Diagnosis of acute cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, myocardial infarction, or heart failure within the 3 months prior to screening.\n3. Presence of other active or significant neurological conditions, including recurrent epileptic seizures, intracranial space-occupying tumors, vascular malformations (including arteriovenous malformations, arterial malformations, or cavernous malformations), or untreated aneurysms with a diameter \\>3 mm.\n4. Severe hepatic impairment \\[ALT or AST \\>3× upper limit of normal (ULN), or concurrent acute hepatitis, chronic active hepatitis, or liver cirrhosis\\], renal impairment \\[estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m²\\], active malignancy, severe anemia, chronic obstructive pulmonary disease (COPD), immune system disorders, uncontrolled diabetes, or uncontrolled hypertension \\[systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg\\].\n5. Currently receiving medications that may interfere with study outcomes.\n6. Known hypersensitivity to the investigational drug or any of its excipients.\n7. Formal education of 1 year or less.\n8. Known history of severe organic disease or an anticipated survival of less than 12 months.\n9. Pregnant or breastfeeding women, or women of childbearing potential who refuse to use contraceptive measures.\n10. Participation in another clinical study within 30 days prior to screening, or currently enrolled in another clinical study.\n11. Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment or unable to complete the study procedures and follow-up visits, such as psychiatric illness or physical conditions that preclude compliance with study requirements.",{"count":226,"type":23},120,[26,228],"PHASE2","This is an exploratory clinical trial aimed at preliminarily evaluating the efficacy, safety, and feasibility of orally administered Gut-X-001 in patients with Alzheimer's disease (AD). An open-label extension (OLE) study will also be conducted to further investigate the effects of Gut-X-001. The study will assess the effects of Gut-X-001 on cognitive function, activities of daily living, neuroimaging indicators, and AD-related plasma biomarkers in AD patients. Safety will be systematically monitored, including the incidence of adverse events and changes in hematological and organ function parameters. Furthermore, the study will explore the regulatory effects of Gut-X-001 versus placebo on venous blood redox-related indicators and gut microbiota metabolite levels at different time points, providing a basis for multi-target intervention strategies and offering systematic evidence for the scientific rationale, feasibility, and safety of Gut-X-001 in the clinical management of AD.",[29],"2026-06-09",{"date":233,"type":39},"2026-06-11",{"date":235,"type":23},"2026-08-01",{"date":237,"type":23},"2027-12-01",{"name":239,"class":88},"Beijing Tiantan Hospital",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":24,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100628309","phase-1-lio-ad-lithium-orotate-in-alzheimers-disease-feasibility-biomarker-engagement-and-clinical-response-100628309","NCT07459959","LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response","LiO-AD","Inclusion Criteria:\n\n* Diagnosis of Alzheimer's disease confirmed by biomarkers (imaging or biofluid evidence of amyloid-beta and tau pathology)\n* Mild stage of Alzheimer's disease: Clinical Dementia Rating (CDR) ≤ 1 or Quick Dementia Rating System (QDRS) ≤ 8\n* Medically stable and able to attend study visits and complete study procedures\n* On stable doses of any psychotropic medications for at least 4 weeks before the baseline visit\n* Not currently receiving anti-amyloid monoclonal antibody therapy\n\nExclusion Criteria:\n\n* New or unstable neurological disorder or unstable psychiatric illness that could affect safety or study results\n* Clinically significant kidney or thyroid problems that pose safety concerns, or abnormal safety labs judged to be related to study drug and requiring discontinuation\n* Use of thiazide diuretics during the dosing period (unless stopped at least 4 weeks before baseline)\n* Chronic daily use of non-aspirin NSAIDs (including COX-2 inhibitors); short courses require study team approval and may require temporary study drug hold and safety labs before resuming\n* Starting excluded therapies during the active treatment period (e.g., anti-amyloid monoclonal antibody treatment)\n* Noncompliance with essential study procedures that would prevent collection of primary safety or feasibility endpoints (e.g., repeated missed visits or refusal of critical labs)",{"count":125,"type":23},[26,228],"The goal of this clinical trial is to assess feasibility, safety, tolerability, and central nervous system target engagement of oral lithium orotate in adults with biomarker-confirmed early Alzheimer's disease. The main questions it aims to answer are:\n\n* Can participants be recruited, retained, and remain adherent (target ≥80%) over 9 weeks of treatment, and what is the frequency and severity of adverse events?\n* Does lithium orotate increase cerebrospinal fluid (CSF) lithium concentration from baseline to 9 weeks compared with placebo? Researchers will compare daily lithium orotate to matched placebo to see if lithium orotate demonstrates acceptable feasibility, safety, and tolerability and engages the central nervous system target (CSF lithium).\n\nParticipants will:\n\n* Be randomized in a double-blind manner to receive lithium orotate or placebo for 9 weeks, with titration from week 1: 240 mg\u002Fday (10mg elemental lithium) to week 2: 480 mg\u002Fday (20mg elemental lithium) and week 3: 720 mg\u002Fday (30mg elemental lithium) if tolerated; dose reductions are permitted for side effects.\n* Attend study visits for safety monitoring, adherence support (caregiver pill logs\u002Fdiaries), and review of concomitant medications and adverse events.\n* Provide blood samples and undergo lumbar punctures at baseline and post-treatment to measure CSF and serum lithium and Alzheimer's-related biomarkers; complete brief cognitive testing and neuropsychiatric symptom assessments.",[29],"2026-06-05",{"date":253,"type":39},"2026-06-08",{"date":185,"type":23},{"date":256,"type":23},"2029-08-31",{"name":258,"class":88},"Johns Hopkins University",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":17,"sex":18,"minAge":266,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":24,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100643540","validation-of-a-remediation-method-for-memory-impairments-through-motor-encoding-in-patients-with-alzheimers-disease-100643540","NCT07632755","Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease","ADACT","Inclusion Criteria:\n\nPatient group: Diagnosis of Alzheimer's disease made by one of the consulting physicians-a neurologist and\u002For geriatrician (Dubois et al., 2014)-at the early stage, presenting with mild memory impairment of which the patient has been informed\n\n\\- MMSE score of 21 or higher\n\nControl group: individuals without a diagnosis of Alzheimer's disease, but meeting the other criteria listed below\n\n* Enrollment in a social security program\n* Age 60 or older\n* French as a native language\n* Consent to participate\n\nExclusion Criteria:\n\n* Uncorrected visual or hearing impairments\n* Language or motor impairments\n* Delirium or psychosis.\n* Medical treatment affecting vision, language, or motor skills (or participation in a study involving a drug or device that influences cognition).\n* Refusal to participate.\n* Inability to communicate\n* Persons deprived of liberty by a judicial or administrative decision and adults subject to a legal protection measure or unable to express their consent","60 Years",{"count":268,"type":23},80,[72],"In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.",[29,272],"Healhty",[132,274,275,276,277,278],"memory remediation","motor-enriched encoding","imagery","static imagery","dynamic imagery","2026-06-02",{"date":253,"type":39},{"date":282,"type":23},"2026-06-20",{"date":284,"type":23},"2028-06",{"name":286,"class":88},"Centre Hospitalier Universitaire de Saint Etienne",3,{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":17,"sex":18,"minAge":96,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":47},"100640934","crownlands-observing-progression-with-neurons-study-100640934","NCT07611396","Crownlands Observing Progression With Neurons Study","Crownlands Observing Progression With Neurons I (CROWN-I)","CROWN-I","Inclusion Criteria:\n\n* Informed consent provided by the participant or, where applicable, Legally Authorized Representative (LAR) or other substitute decision-maker where permitted by applicable law, as described in Section 8.2.\n* Male or female, age ≥ 55 years at Screening.\n* Fluency of subject and study partner in English sufficient to complete all cognitive and self-report assessments without interpreter assistance.\n* Adequate visual and auditory acuity (with correction permitted) sufficient to complete neuropsychological testing.\n* Not pregnant or lactating.\n* Medications stable ≥ 4 weeks before screening.\n* GDS-15 \\\u003C 6 (i.e., 0-5 inclusive; no current significant depression).\n* Available study partner who has known the participant for ≥ 12 months, maintains \\~10+ hours per week of in-person or telephone contact, and is willing to attend study visits and complete informant-rated assessments.\n* Willing to complete olfactory brushing, smell testing, and venous blood draw.\n* Willing to commit to baseline and follow-up visits across study duration.\n* In the opinion of the Investigator, able to comply with the protocol-specified visit schedule and procedures for the full study duration.\n\nExclusion Criteria:\n\n* Current or active clinically significant neurological disorder (in the opinion of the Investigator) other than the disorders in the study arms, including but not limited to:\n* Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, Huntington's disease, prion disease, multi-infarct dementia, normal pressure hydrocephalus, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, significant head trauma with persistent deficits, or known structural brain abnormalities.\n* Active or unstable major psychiatric illness (DSM-5 schizophrenia spectrum, bipolar I, or severe major depressive disorder with active suicidality) within 6 months prior to Screening; history of schizophrenia at any time.\n* Psychotic features, agitation, or behavioral problems within the last 3 months that could interfere with protocol compliance.\n* Current substance use disorder (DSM-5 moderate or severe), or alcohol use disorder within 24 months prior to Screening.\n* Active malignancy under treatment, or malignancy with expected survival \\\u003C 30 months (excluding non-melanoma skin cancer and localized prostate cancer on active surveillance).\n* Participation in studies collecting neuropsychological measures more than once per year.\n* Presence of previous nasal surgery or other anatomical abnormalities that could interfere with the procedure on both sides of the nose, at the discretion of the clinician administering the Olfactory Brushing.\n* Active respiratory infection or recent history of respiratory infection within the past two weeks.\n* Known allergy or adverse reaction to topical anesthetics or decongestants used in the study (e.g., lidocaine, tetracaine, oxymetazoline).\n* Any other medical or psychiatric condition or lab abnormality that, in the opinion of the Investigator, might preclude participation or render the participant unsuitable for study enrollment.\n\nCognitively Normal (CN) Additional Inclusion Criteria (CN)\n\n* No subjective cognitive complaint reported by participant AND no cognitive -complaint reported by study partner.\n* No current or prior clinical diagnosis of MCI, Alzheimer's disease, or any other dementia, and no current clinical diagnosis of a neurological or neuropsychiatric disease.\n* MMSE score ≥ 27 \u002F 30 at Screening.\n* Global Clinical Dementia Rating (CDR) = 0 at Screening.\n* CDR Sum of Boxes (CDR-SB) = 0 at Screening.\n* Performance within 1.0 standard deviation of demographically adjusted norms on the Rey Auditory Verbal Learning Test (RAVLT) Delayed Recall.\n\nAdditional Exclusion Criteria (CN)\n\n* Current or prior use of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or memantine for any indication.\n* Current or prior use of anti-amyloid monoclonal antibody disease-modifying therapy (aducanumab, lecanemab, donanemab, or any investigational anti-amyloid mAb).\n\nMild Cognitive Impairment (MCI) Additional Inclusion Criteria (MCI)\n\n* Subjective cognitive complaint reported by participant OR partner-verified memory complaint reported by study partner.\n* MMSE score ≥ 24 and ≤ 30 at Screening.\n* Global CDR = 0.5 at Screening.\n* CDR-SB ≥ 0.5 and \\\u003C 3 at Screening; CDR Memory Box ≥ 0.5.\n* Performance ≥ 1.5 standard deviations below demographically adjusted norms on the RAVLT Delayed Recall (or equivalent episodic memory criterion per the Petersen \u002F NIA-AA MCI framework).\n* Preserved general functional ability such that the participant does not meet criteria for dementia (i.e., does not meet AD criteria in Section 7.3).\n\nAlzheimer's Disease (AD) Additional Inclusion Criteria (AD)\n\n* Confirmed clinical diagnosis of probable Alzheimer's disease by a qualified specialist (cognitive neurologist, geriatric psychiatrist, or equivalent), consistent with NIA-AA 2011 (McKhann et al.) or NIA-AA 2018 Research Framework biological criteria.\n* MMSE score ≥ 16 and ≤ 26 at Screening.\n* Global CDR ≥ 1 at Screening.\n* CDR-SB ≥ 3 at Screening.\n* CDR Memory Box score ≥ 0.5 at Screening.\n* Partner-verified history of progressive cognitive decline of ≥ 6 months duration.\n* Functional impairment consistent with dementia, as documented on the CDR Functional Domains (Community Affairs, Home \\& Hobbies, Personal Care); participant able to complete protocol.",{"count":297,"type":23},160,"OBSERVATIONAL","The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The primary objective is to identify the molecular and genetic modules that differentiate patient subtypes and predict progression of AD. Participants will visit clinical sites to donate samples multiple times and perform virtual and in-person clinical assessments.",[29,301],"Mild Cognitive Impairment (MCI)",[303,304,305,306,307],"alzheimer's","longitudinal","genetics","olfactory neurons","biomarkers",{"date":309,"type":39},"2026-06-04",{"date":311,"type":39},"2026-05-19",{"date":313,"type":23},"2029-05",{"name":315,"class":216},"Crownlands",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":223,"eligibilityCriteria":322,"healthyVolunteers":17,"sex":18,"minAge":197,"maxAge":149,"enrollmentInfo":323,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":47},"100639539","subjective-assessment-of-spatial-orientation-abilities-in-alzheimers-disease-100639539","NCT07616063","Subjective Assessment of Spatial Orientation Abilities in Alzheimer's Disease","Evaluation Subjective Des CApacités d'Orientation sPatialE Dans la mAladie D'Alzheimer","Inclusion Criteria:\n\nFor all subjects :\n\n* Native French speakers\n* Independent mobility: (minimum mobility range of 3 (i.e., neighborhood) on the LSA-F assessment of the mobility zone scale)\n* Person affiliated with a social security system or beneficiary of such a system\n\nPatients (Subgroup A1) and healthy control subjects (Group C):\n\n* Individuals who have received complete information about the clinical research organization and have signed their written informed consent\n* Patients (Subgroups A2 and A3) and Companions (Group B) Individuals who have received complete information about the clinical research and have agreed to participate\n\nPatients (group A):\n\n* Aged 55 to 85\n* Diagnosis of probable Alzheimer's disease (NINCDR-ADRDA diagnostic criteria)\n* Score of 4 or less on the Hachinski Ischemic Scale\n* Score of 20 or higher on the Folstein MMSE (Mini Mental State Examination)\n* In the case of specific treatment for Alzheimer's disease (anticholinesterase and memantine treatments), treatment stability for \\> 15 days\n* Able to walk independently, i.e., without assistance, whether human or technical, except for a simple cane\n\nCaregivers (group B):\n\n* Caregivers of a person with dementia included in group A, with regular contact (at least 10 hours per week, spread over a minimum of 3 times per week)\n* Healthy control subjects (group C):\n* Aged 55 to 85\n* Able to walk independently, i.e., without assistance, whether human or technical, except for a single cane\n* Normal performance on the Folstein Mini-Mental State Examination (MMSE), according to GRECO (Cognitive Assessment Task Force) standards\n\nExclusion Criteria:\n\nFor all subjects:\n\n* Adults subject to legal protection measures (guardianship, curatorship, judicial protection)\n* Adults unable to give their consent\n* Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1.\n* Persons capable of giving consent but unable to read French\n* Persons capable of giving consent but unable to write\n* One of the members of the patient\u002Fcaregiver dyad refusing to participate in the study.\n\nPatients (subgroup A1) and healthy control subjects (group C):\n\n* Sensory or phasic deficit interfering with the task.\n* History of moderate or severe head trauma (with loss of consciousness).\n* Change in psychotropic treatment less than 48 hours before the tests\n* Chronic alcoholism\n* Severe depression (score greater than or equal to 10 on the GDS-15 Geriatric Depression Scale)\n* Presence of other clinically significant psychiatric or neurological conditions (except Alzheimer disease for case subjects)",{"count":324,"type":23},330,"Difficulty orienting oneself and finding one's way around the environment, also known as \"topographical disorientation\" (TD) or \"spatial disorientation\" (SD), is a common and often early symptom of Alzheimer's disease (AD) that affects people's independence and well-being. Being able to identify it is therefore crucial in order to provide appropriate support.\n\nIt cannot be assessed using conventional psychometric tests due to its low ecological validity. Several subjective assessment scales have been created to screen for SD \"spatial disorientation\" and assess its functional and psychological impact. However, none of these scales have been translated and validated in French. As a result, DS is not assessed in routine clinical practice.\n\nAmong these scales, the Wayfinding Questionnaire (WQ) explores three dimensions: spatial orientation, distance estimation, and spatial anxiety. This questionnaire has undergone psychometric validation studies in its original Dutch version for a population with mild post-stroke , and norms for the general population have been published.\n\nOur team translated this questionnaire into French (i.e., \"Questionnaire d'Orientation Spatiale\" (QOS)) and adapted it cross-culturally to preserve the qualities of the measurement. A \"Caregiver\" version was also created, taking into account the anosognosia known to occur in AD. Primary Objective : Evaluate the psychometric properties of the Spatial Orientation Questionnaire (SOSQ) (i.e., the French translation and adaptation of the Wayfinding Questionnaire) in assessing spatial orientation disorders in patients with Alzheimer's disease, in both its \"patient\" and \"caregiver\" versions. Secondary objective : Evaluate the acceptability of the Spatial Orientation Questionnaire (SOC) in its \"patient\" and \"caregiver\" versions.",[29,327],"Spatial Orientation",[329],"Alzheimer s disease","2026-05-26",{"date":332,"type":39},"2026-05-29",{"date":334,"type":23},"2026-05",{"date":336,"type":23},"2026-11",{"name":338,"class":88},"Central Hospital, Nancy, France",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":346,"enrollmentInfo":347,"targetDuration":349,"studyType":298,"phases":4,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":47},"100621227","the-monument-test--a-new-tool-for-assessing-the-ability-to-name-and-identify-unique-entities-tedimo-100621227","NCT07367880","The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)","TeDIMO","Inclusion criteria :\n\n* Alzheimer's disease:\n\n  * Age ≥ 50 years and older\n  * Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011.\n  * Score 18≤ MMSE ≤26\n* Controls:\n\n  * Age ≥ 50 years and older\n  * MMSE score ≥ 26 For all subjects\n  * No objection from the participant\n\nExclusion criteria\n\n* Alzheimer's disease:\n\n  * Persons referred to in Articles L1121-5 to L1121-8 of the CSP\n* Controls:\n\n  * Memory complaints\n  * Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects\n  * Significant neurological or psychiatric history\n  * Taking psychotropic medication (neuroleptics)\n  * Poor command of the French language, comprehension difficulties\n  * Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.)\n  * Insufficient exposure to the media and\u002For socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)","95 Years",{"count":348,"type":23},220,"1 Month","The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.",[29],[353,354,355,356],"unique entities","denomination","identification","landmarks","2026-05-22",{"date":330,"type":39},{"date":360,"type":39},"2026-02-23",{"date":362,"type":23},"2032-02-01",{"name":364,"class":88},"University Hospital, Grenoble",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":123,"enrollmentInfo":372,"targetDuration":4,"studyType":24,"phases":374,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":47},"100640973","phase-4-evaluating-the-efficacy-and-safety-of-lecanemab-in-alzheimers-disease-through-multi-omics-approachs-100640973","NCT07604896","Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs","Multicenter, Randomized, Controlled Study Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs","Inclusion Criteria:\n\n* Age: 50 to 90 years old.\n* No gender restrictions.\n* Patients with MCI and mild AD.\n* The MMSE score is ≥20, and the overall CDR score is 0.5 or 1 point.\n* Positive Amyloid protein confirmed by amyloid-PET or CSF.\n* There is a reliable caregiver accompanying the patient during the research visit and supervising the use of the study drug during the trial.\n* Agree to participate in the research and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with cognitive impairment caused by reasons other than AD.\n* There was a history of transient ischemic attack (TIA), stroke, cerebral hemorrhage or epileptic seizure within 12 months prior to screening.\n* A Hamilton Depression Scale score of more than 17 at the time of screening, or any suicidal behavior within 6 months before screening, during screening, or at baseline visits, as well as other psychiatric diagnoses or symptoms (such as hallucinations, anxiety disorders, or delusions) that interfere with the research process of the subjects.\n* Patients with hemorrhagic diseases or those receiving anticoagulant therapy, as well as any patients with malignant tumors, severe gastrointestinal, kidney, liver, respiratory, immune, endocrine and cardiovascular system diseases that affect this study.\n* There is a hypersensitivity reaction to lecanemumab or any other component in the injection solution or any monoclonal antibody treatment.\n* There are contraindications for MRI scans, including the installation of cardiac pacemakers\u002Fdefibrillators and ferromagnetic metal implants (except for cranial and cardiac devices approved for safe use in MRI scans).\n* There is a known or suspected history of drug or alcohol abuse or dependence within two years prior to screening.\n* Subjects who participated in clinical studies involving any therapeutic monoclonal antibodies or novel compounds for the treatment of AD within 6 months prior to screening, unless it can be demonstrated that the subjects were in the placebo treatment group.\n* Surgical operations under general anesthesia are planned to be performed during the research period.\n* Women who have positive pregnancy test results, are breastfeeding or pregnant at the time of screening or baseline.",{"count":373,"type":23},200,[375],"PHASE4","This research proposal outlines a multi-center, randomized, trial. Patients diagnosed with early-to-moderate Alzheimer's Disease will be recruited. Participants will be randomly assigned to receive either Lecanemab. The study will run over a period of 24 months, with evaluations conducted at baseline, 6 months, and 12 months, 18 months and 24 months. Data from multiple omics layers will be integrated to assess both the efficacy and safety of the treatment.\n\nThe primary aim of this study is to assess the efficacy and safety of Lecanemab in patients with Alzheimer's Disease, leveraging multi-omics approaches. Specifically, the study will integrate data from OCT\u002FOCTA imaging of the eye and MRI imaging of the brain, as well as cognitive measures such as ADAS-Cog, MoCA and CDR scores. Furthermore, the presence of ARIA-a significant safety concern in amyloid-targeting therapies-will be closely monitored. The study seeks to provide a more robust understanding of Lecanemab's impact on disease progression, cognition, and potential adverse effects, contributing to a more informed clinical application of this treatment in Alzheimer's care.",[29,378,379],"Alzheimer Dementia (AD)","MCI-AD, Early Stage Alzheimer's Disease","2026-05-17",{"date":357,"type":39},{"date":383,"type":39},"2026-01-01",{"date":385,"type":23},"2028-12-31",{"name":387,"class":88},"First Affiliated Hospital of Wenzhou Medical University",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":197,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":47},"100640268","ultrasonic-debris-clearance-to-promote-brain-resilience-100640268","NCT07573982","Ultrasonic Debris Clearance to Promote Brain Resilience","Safety and Feasibility Trial of Ultrasonic Debris Clearance to Promote Brain Resilience","Inclusion Criteria:\n\n1.1. Physician-reported amyloid positivity diagnosed by amyloid positron emission tomography (PET) OR historic CSF positivity of Abeta42, total tau, or phosphorylated tau OR positivity of plasma pTau-217.\n\n1.2. Age ≥ 18 years. No gender\u002Fsex, racial, or ethnic preference. Subjects greater than 60 years of age will be assumed to be non-pregnant based on age and expected post-menopausal status. Female subjects under the age of 60 will complete a two-step assessment of pregnancy status (a self-reported assessment of menopause that proceeds to a urine human chorionic gonadotropin (hCG) test to confirm non-pregnancy, if the participant is not post-menopausal).\n\n1.3. CDR Scale score less than or equal to 1.0, consistent with mild, very mild, or no dementia.\n\n1.4. Ability and willingness to comply with the study procedures (six sessions sitting in a procedure chair for up to one hour for the procedure, with an ultrasound device placed on their scalp; additional time for the MRI assessment, blood draws, and cognitive assessments).\n\n1.5. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n2.1. Dementia of moderate or higher severity (CDR \\> 1.0) 2.2. Intracranial tumors, acute or chronic hemorrhage (beyond petechiae\u002Fmicrohemmorhage), or other current or historic central nervous system specific pathology. Baseline MRI studies will be screened by the protocol director to ensure no exclusionary intracranial pathology is present.\n\n2.3. Any other comorbidity that would prevent adequate interpretation of the study results per the treatment team (e.g. congenital brain malformations without clinical importance) 2.4. Ultrasound attenuators along the ultrasound beam path (metal, air, or bulky calcification) including thick hair or related adornments that cannot be undone for the study (e.g. turbans, dreadlocks, hairweaves\u002Fwigs) that would prevent adequate ultrasound gel coupling of the device to the scalp or could trap air in the ultrasound beam path.\n\n2.5. Contraindications to MRI (unknown device, claustrophobia) or metallic hardware in the head that prevent adequate MRI visualization of the brain 2.6. Allergy or similar intolerance to the materials used for ultrasound device coupling (ultrasound gel, silicone) 2.7. Receipt of anti-amyloid monoclonal antibody therapy within 6 months prior to screening 2.8. Moderate or greater depressive symptoms at screening, defined as a Patient Health Questionnaire-9 (PHQ-9) total score \\>= 10.\n\n2.9. Clinically significant suicidal ideation or behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) 2.10. Clinically significant hematologic abnormalities, defined as hematocrit \\\u003C 35% for male or \\\u003C 32% for female, absolute neutrophil cell count \\\u003C 1500\u002FuL, absolute lymphocyte count \\\u003C 900\u002FuL, or platelet count \\\u003C 120,000\u002FuL 2.11. Clinically significant hepatic, renal, respiratory, cardiovascular, or metabolic disease that increases risk or interferes with interpretation, defined as ALT\u002FAST\u002FALP \\> 1.5 ULN, or eGFR \\\u003C 50 mL\u002Fmin\u002F1.73m2, or recent MI\u002Funstable angina\u002FHF\u002Fcardiomyopathy within 6 months, 2.12. Significant bradycardia(\\\u003C50\u002Fmin) or tachycardia (\\>100\u002Fmin) 2.13. Poorly controlled BP 2.14. Uncontrolled diabetes, defined as HbA1c \\> 7.5 2.15. Active clinically significant infection or other systemic illness affecting the CNS",{"count":396,"type":23},15,[72],"This pilot study will evaluate the safety, tolerability, and feasibility of Ultrasonic Debris Clearance (UDC), a noninvasive low-intensity focused ultrasound intervention, in amyloid-positive adults who are asymptomatic but at risk for Alzheimer's disease, or who have mild cognitive impairment or mild dementia. The study is designed to test whether repeated UDC sessions can be delivered safely and feasibly in this population, while also exploring efficacy via biomarkers and clinical measures.",[29,400],"MCI With Increased Risk for Alzheimer Disease","2026-05-01",{"date":403,"type":39},"2026-05-07",{"date":405,"type":23},"2026-07",{"date":407,"type":23},"2027-07",{"name":409,"class":88},"Stanford University",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":197,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":434,"locationsCount":47},"100618487","phase-1-alzheimers-disease-and-faecal-microbiota-transplantation--a-pilot-study-100618487","NCT07332260","Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study","Alzheimer's Disease and Faecal Microbiota Transplantation","AD-FMT","Inclusion Criteria:\n\n* Alzheimer's dementia mild to moderate stage\n* Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024)\n* Capable of giving informed consent\n\nExclusion Criteria:\n\n* Contraindications for colonoscopy examination\n* Contraindications for Magnetic Resonance Imaging (MRI)\n* Life expectancy \\\u003C 1 year\n* Clinical frailty scale 7 or more\n* History of seizure disorder\n* History of brain tumour or intracranial bleed\n* Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder\n* Alcohol or substance abuse\n* Decompensated heart disease\n* Malignancy\n* Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin)\n* Pregnant or planning pregnancy\n* Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy\n* Status after colectomy or hemicolectomy\n* Inflammatory bowel disease\n* Immunocompromised individual\n* Receiving biological\u002Fantibody treatment",{"count":419,"type":23},10,[26],"The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.",[29,423],"Faecal Microbiota Transplantation (FMT)",[132,102,425,426,427],"Gut microbiota","faecal microbiota transplantation","FMT","2026-04-17",{"date":430,"type":39},"2026-04-22",{"date":334,"type":23},{"date":433,"type":23},"2027-01",{"name":435,"class":88},"University Hospital of North Norway",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":266,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":24,"phases":446,"briefSummary":447,"conditions":448,"keywords":453,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":47},"100614447","phase-2-fisetin-in-mild-alzheimers-disease-100614447","NCT07279714","Fisetin in Mild Alzheimer's Disease","Fisetin Intervention Study in Mild Alzheimer's Disease","FIS-AD","Inclusion Criteria:\n\n* Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia\n* Moca score of 11 or higher\n* Stable psychotropics and cognitive enhancing medications\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to fisetin\n* Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial\n* Unstable medical disorders\n* Ongoing treatment for active infection with antibiotics\u002Fantifungals\n* Ongoing treatment for cancer\n* Active alcohol or substance use disorder\n* Recent active bleeding\n* Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin\n* Use within the last month of other senolytic supplements, antioxidant supplements, natural health products\n* Other neurologic or neurodegenerative conditions impacting cognition\n* Active Major Depressive Episode, active suicidal thoughts or psychosis\n* Any thing that would preclude the ability to undergo an MRI scan",{"count":445,"type":23},5,[228],"This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.",[29,449,378,178,450,451,452],"Alzheimer Dementia","Mild Cognitive Disorder","Neurocognitive Disorders, Mild","Neurocognitive Disorder",[454,455,456,457],"fisetin","alzheimer's disease","safety","tolerability","2026-04-10",{"date":460,"type":39},"2026-04-13",{"date":462,"type":39},"2026-01-27",{"date":336,"type":23},{"name":465,"class":88},"Sunnybrook Health Sciences Centre",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":17,"sex":18,"minAge":197,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":24,"phases":475,"briefSummary":476,"conditions":477,"keywords":492,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":504,"locationsCount":4},"100619558","communityrx-dementia--peer-navigation-crxdpeer-100619558","NCT07346183","CommunityRx-Dementia + Peer Navigation (CRxDpeer)","CommunityRx-Dementia + Peer Navigation (CRxDpeer): A Real-World Implementation and Effectiveness Study of an IT-Based Social Care Intervention","CRxDpeer","Inclusion Criteria:\n\n* Self-identifies as a caregiver of a home-dwelling person with Alzheimer's disease or related dementias (ADRD)\n* Resides in the target geographic region of the study\n* Has access to a cell phone and agrees to receive text messages from the study\n* Has an email address that they can receive emails from\n* Individuals under the age of 18 who are emancipated minors in the state of Illinois and a caregiver of a person with dementia\n\nExclusion Criteria:\n\n* Minors who are not emancipated in the state of Illinois.\n* Previously participated in the intervention arm of the CommunityRx-Dementia clinical trial",{"count":324,"type":23},[72],"The CRxDpeer intervention, delivered by a trained peer navigator, in practice called a \"peer mentor\", includes three evidence-based components: (a) focused education about common social (e.g., food and housing insecurity) and caregiving (e.g., respite and end of life care) needs, (b) activation of personalized community resource information for social and caregiving needs through delivery of a resource list (HealtheRx) at the baseline encounter and coaching on how to communicate with service providers, coordinate services and manage social support (e.g., connect with their peer navigator, reach out to friends or relatives for support, identify support groups, etc.) and (c) ongoing navigation-focused support meant to boost the baseline intervention, including a series of proactive text messages over 12 months. During this time, the subject can respond to and communicate with the peer navigator for ongoing support.",[29,102,478,479,480,481,482,483,484,485,486,487,488,489,490,491],"Caregiver","Loneliness","Health-Related Social Needs","Social Care","Healthcare Utilization","End of Life Care","Caregiver Burden","Anxiety","Stress","Depression","Self-Efficacy","Peer Support","Implementation Science","Advance Care Planning",[493,494,495,496,497],"resource navigation","peer navigator","peer mentor","social care","dementia caregiver","2026-04-06",{"date":500,"type":39},"2026-04-07",{"date":112,"type":23},{"date":503,"type":23},"2029-02-28",{"name":505,"class":88},"University of Chicago",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":17,"sex":18,"minAge":266,"maxAge":149,"enrollmentInfo":513,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":47},"100630063","dementia-in-fiction-and-clinical-narratives-100630063","NCT07482800","Dementia in Fiction and Clinical Narratives","Examining Representations of Dementia in Fiction and Clinical Narratives","Inclusion Criteria:\n\n* Diagnosed with early-stage Alzheimer's disease or other mild cognitive impairment by a neurologist (case group) \u002F healthy individuals matched for age and education level (control group)\n* Able to communicate and understand basic language\n\nExclusion Criteria:\n\n* Refuse to participate in the study",{"count":125,"type":23},"This study aims to compare the natural narrative language of patients with Alzheimer's disease and the fictional depictions of dementia in contemporary novels from both neurological and literary perspectives. It investigates the similarities and differences in the deterioration of semantic and episodic memory. The goal is to develop a cross-disciplinary language observation model that enhances early diagnostic understanding, fosters empathy in caregiving, and strengthens medical humanities education.",[102,29],[102,517,518,519,520],"Language Decline","Neurology","Narrative Medicine","Literary Analysis","2026-03-18",{"date":523,"type":39},"2026-03-20",{"date":525,"type":39},"2026-03-17",{"date":527,"type":23},"2026-07-31",{"name":529,"class":88},"Fu Jen Catholic University",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":197,"maxAge":4,"enrollmentInfo":537,"targetDuration":349,"studyType":298,"phases":4,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":4},"100629347","assessment-of-malnutrition-in-hospitalized-patients-a-quasi-study-100629347","NCT07473492","Assessment of Malnutrition in Hospitalized Patients: a Quasi Study","AMMRP","Inclusion Criteria:\n\n* Age: Adult patients aged $\\\\ge$ 18 years.Setting: Patients admitted to the Medicine, Surgery, or Neurology Intensive Care Unit (ICU) wards at Al-Basrah Teaching Hospital or Al-Fayhaa General Hospital.Duration of Stay: Patients who have been hospitalized for a minimum of 48 hours (to ensure a baseline for malnutrition screening and medication review).Clinical Conditions: Patients with various primary diagnoses, including specific subgroups with Chronic Obstructive Pulmonary Disease (COPD) and Alzheimer's Disease.Informed Consent: Patients or their legal guardians (especially for those in the ICU or with cognitive impairment) who provide written or verbal informed consent.\n\nExclusion Criteria:\n\n* Maternity\u002FObstetrics: Pregnant or lactating women, as nutritional requirements and physiological BMI changes differ from the general adult population.\n\nTerminal Illness: Patients in end-of-life or palliative care where nutritional intervention is no longer a clinical goal.\n\nIncomplete Records: Patients with missing medical or medication charts that prevent the accurate identification of Medication-Related Problems (MRPs).\n\nShort Stay: Patients planned for discharge or transfer within less than 48 hours of admission.\n\nPsychiatric Disorders: Patients with primary psychiatric diagnoses that may interfere with the ability to conduct nutritional assessments (unless a guardian is present).",{"count":538,"type":23},300,"Malnutrition among hospitalized patients is a critical, yet often overlooked, public health issue associated with increased complications, longer hospital stays, higher mortality, and greater healthcare costs. In Iraq, factors such as dietary patterns, the burden of chronic diseases, and healthcare constraints may increase the risk of hospital-acquired malnutrition. Current standard care may not include systematic nutritional screening or protocol-driven support. This trial aims to test whether implementing an individualized nutritional support program can improve clinical outcomes for at-risk medical inpatients in Iraqi hospitals, building upon evidence from international studies",[541,78,29],"COPD , Neurology , ICU",[543,544],"Hospital Malnutrition , Nutritional Risk Screening ,GLIM Criteria","Medication-Related Problems (MRPs","2026-03-11",{"date":547,"type":39},"2026-03-16",{"date":549,"type":23},"2026-04-01",{"date":551,"type":23},"2026-09-01",{"name":553,"class":88},"AlFayhaa General Hospital",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":17,"sex":18,"minAge":266,"maxAge":561,"enrollmentInfo":562,"targetDuration":4,"studyType":24,"phases":564,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":580},"100612289","adaptation-of-the-mini-mental-state-examination-mmse-for-the-reunion-island-population-100612289","NCT07251647","Adaptation of the Mini-Mental State Examination (MMSE) for the Reunion Island Population","MMSE-RUN","Inclusion criteria:\n\n* For the healthy population : aged 60 to 89 years, residing in Reunion for more than 5 years, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.\n* For the sick population : aged 60 to 89 years, residing in Reunion for more than 5 years, presenting probable or possible Alzheimer's disease and\u002For probable vascular cognitive disorder, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.\n\nExclusion criteria:\n\n* For the healthy populationhistory of neurological pathology, neurodegenerative pathology with cognitive expression, refusing to participate in the study, under legal protection.\n* For the sick population: acute unresolved medical decompensation or acute psychic decompensation, refusing to participate in the study, under legal protection.","89 Years",{"count":563,"type":23},400,[72],"The Mini-Mental State Examination (MMSE) is the most widely used cognitive screening and monitoring test for neurocognitive disorders in current clinical practice. Its French version was published in 1998 by the GRECO group (MMSE-GRECO). However, some items of this French version are not adapted to local Reunionese particularities.\n\nThe main objective is to propose and validate the psychometric properties of an adapted version of the MMSE, to the Reunionese culture (MMSE-RUN) in a healthy population and in a sick population (Alzheimer's Disease and Vascular Cognitive Disorder), and to compare its performance with the MMSE-GRECO.",[29,567],"Vascular Cognitive Impairment",[569,570,571,572],"Neurocognitive disorder","cognitive test","screening","Reunion Island",{"date":574,"type":39},"2026-03-12",{"date":576,"type":23},"2026-04",{"date":407,"type":23},{"name":579,"class":88},"Centre Hospitalier Universitaire de la Réunion",7,{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":17,"sex":18,"minAge":197,"maxAge":4,"enrollmentInfo":589,"targetDuration":591,"studyType":298,"phases":4,"briefSummary":592,"conditions":593,"keywords":596,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":47},"100628885","precision-medicine-and-neurodegenerative-diseases-advanced-systems-for-the-diagnosis-and-treatment-of-parkinsons-disease-and-alzheimers-disease-100628885","NCT07467460","Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.","NEUROTECHNO: Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.","NEUROTECHNO","Inclusion Criteria:\n\n* -Inclusion Criteria:\n* Inclusion criteria for PD patients. For the IRCCS INM Neuromed, patients will be recruited from those affiliated with the Center for the Study and Treatment of Parkinson's Disease of the Neuromed Institute of Pozzilli.\n\nPresence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, asymmetric onset), one of which must be tremor or bradykinesia:\n\nAbsence of atypical symptoms such as: i) early postural instability, freezing episodes, cognitive decline, hallucinations, pathological involuntary movements, vertical gaze palsy; ii) confirmed causes of secondary parkinsonism (focal lesions, medications, toxic substances); Documented response to L-dopa or dopamine agonists (or lack of an adequate therapeutic trial with L-dopa or dopamine agonists).\n\n-Inclusion criteria forAD patients. For the University of Campania, patients will be selected at the Department of Advanced Medical and Surgical Sciences of the University of Campania \"L. Vanvitelli,\" located at Piazza Miraglia 2, Naples. The Department will establish a collaboration with the Alzheimer's day centers of ASL NA1 (Geriatric Facility \"Villa Walpole\" - Via Ponti Rossi, 118 - Naples, and Geriatric Facility \"Frullone\" - Via Comunale del Principe, 16\u002FA - Naples) to identify potential subjects for screening to verify the parameters required for recruitment. The Geriatrics and Internal Medicine Unit (UOC), AOU University of Campania, will also be involved.\n\nPatients with AD will be included following a diagnosis of probable Alzheimer's disease according to the McKhann criteria (2011), supported by positive biomarkers for amyloidopathy (amyloid PET or cerebrospinal fluid amyloid assay).\n\nExclusion Criteria:\n\n* Pre-existing psychiatric disorders;\n* Neurodegenerative neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, neuromuscular disorders, epilepsy;\n* Diagnosis of dementia.",{"count":590,"type":23},500,"24 Months","In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the prevalence of age-related diseases. Among these, Alzheimer's disease (AD), Parkinson's disease (PD), and type 2 diabetes (T2D) currently represent a major threat to human health. PD and AD are the most common neurodegenerative diseases in industrialized populations. In particular, AD accounts for 54% of all cases of dementia, with a prevalence of 4.4% among individuals over 65 years of age. PD has a prevalence of about 1% in people older than 60 years, reaching up to 4% in those over 80 years of age. AD and PD are highly disabling disorders with a slow but progressive course, caused by the degeneration and\u002For death of nerve cells. This results in impairments in the control of movement and balance, as in the case of PD, or in cognitive functioning, as in AD.\n\nTo date, neither effective treatments nor early diagnostic tools are available to address these conditions in the initial phase of neurodegeneration. Likewise, there are no tools capable of monitoring disease progression and improving patients' adaptation to therapy.\n\nMoreover, although the association between T2D and the risk of PD and\u002For AD has long been recognized, these conditions were historically considered unrelated. Recent evidence from clinical and epidemiological studies suggests the existence of shared pathophysiological mechanisms associated with insulin resistance and persistent inflammation in several metabolically relevant tissues, such as adipose tissue and the brain. However, the mechanisms that increase the risk of PD and\u002For AD in individuals with T2D remain poorly understood.\n\nThese data highlight how relevant these diseases are for the National Health System and demonstrate that they represent one of the most important priorities to be addressed, requiring substantial investments in both scientific research and early diagnostic strategies.\n\nTherefore, the present project proposal, which aims to develop new minimally invasive tools for the early prediction and monitoring of neurodegenerative diseases such as AD and PD, will help fill an important gap in the clinical and therapeutic management of these patients.",[594,29,595],"PARKINSON DISEASE (Disorder)","Diabete Type 2",[597,598,599],"Identification of genetic and metabolic profiles associated with neurodegenerative diseases","Identification of epigenetic profiles associated with neurodegenerative diseases","Integration and analysis of omics and neuroimaging data","2026-03-09",{"date":574,"type":39},{"date":603,"type":39},"2026-02-17",{"date":605,"type":23},"2028-09-30",{"name":607,"class":88},"Neuromed IRCCS",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":18,"minAge":266,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":617,"conditions":618,"keywords":621,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":47},"100624428","assessment-of-informal-support-provided-by-caregivers-at-different-stages-of-alzheimers-disease-100624428","NCT07409506","Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease","ICAD","Inclusion Criteria:\n\n* Patients from Charpennes Hospital included in the MEM-AURA cohort\n* Patients aged 60 years and older at inclusion\n* Patients with dementia due to clinically probable Alzheimer's disease, regardless of stage\n* Patients with a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion\n* Patients accompanied by a caregiver at inclusion\n\nExclusion Criteria:\n\n* \\- Patients or caregivers who have expressed their opposition to the study\n* Patients living in institutions or nursing homes\n* Patients protected by law (under legal protection, guardianship, or conservatorship)\n\nEarly termination Criteria :\n\n\\- Patients or caregivers withdrawing their consent to participate during the study",{"count":616,"type":23},312,"In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system.\n\nInformal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation of informal care serves to inform public decision-makers not only about the cost of this resource, but also about its usefulness. The issue of resource allocation (particularly the daily allowance for family caregivers - AJPA in French) at the societal level and the sharing of private (role of caregivers) and public (role of the state and local authorities) responsibilities leads us to question the determinants of this usefulness, particularly the clinical determinants in AD patients at different stages of the disease.\n\nThe main hypothesis is that informal care varies according to cognitive decline and loss of autonomy, independently or in interaction with the number and type of the patient's comorbidities, their behavioral disorders, and the caregiver's burden.",[619,620,29],"Elderly (People Aged 65 or More)","Neurocognition",[622,623,624],"informal care","cost of alzheimer's disease","caregiver","2026-02-12",{"date":627,"type":39},"2026-02-13",{"date":629,"type":39},"2025-09-09",{"date":631,"type":23},"2027-09-09",{"name":633,"class":88},"Hospices Civils de Lyon",{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":17,"sex":18,"minAge":197,"maxAge":68,"enrollmentInfo":641,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":643,"conditions":644,"keywords":646,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":47},"100623878","vr-pupillometry-in-cognitive-impairment-100623878","NCT07402356","VR Pupillometry in Cognitive Impairment","Task-evoked Pupillometry in AD, MCI, and Depression-Related Cognitive Impairment","Inclusion Criteria:\n\n1. Written informed consent.\n2. Age 18-80 years.\n3. Ability to read and understand German.\n4. For patient cohorts: suspected or confirmed diagnosis of AD\u002FMCI\u002Fdepressive disorder with cognitive impairment according to clinical assessment and routine documentation.\n\nExclusion Criteria:\n\n1. Acute suicidality (e.g. BDI suicidality item \\> 1).\n2. Change of psychotropic medication within the last 4 weeks.\n3. Lifetime psychotic disorder (ICD-10 F20-29).\n4. Lack of capacity to consent.\n5. Lifetime bipolar disorder (ICD-10 F31).\n6. Acute substance abuse or harmful use of alcohol or other psychoactive substances.\n7. Parkinson's syndrome (ICD-10 G20).\n8. Multiple sclerosis (ICD-10 G35).\n9. Stroke within the last 12 months.",{"count":642,"type":23},140,"With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 3 and 6 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.",[29,645,30,102],"Major Depressive Disorder (MDD)",[104,647,30,102,648,649,650,651],"Major Depressive Disorder","Pupillometry","Biomarkers","Amyloid beta-Peptides","Tau Proteins",{"date":603,"type":39},{"date":654,"type":39},"2025-05-01",{"date":656,"type":23},"2027-12-31",{"name":658,"class":88},"Max-Planck-Institute of Psychiatry"]